PBGENE-DMD — Initial data
Late 2026
We are grateful to the patient, their family, and the clinical team for their commitment to advancing this important work, and we look forward to reporting initial safety data by year-end 2026.Source filing
DTIL biotech catalysts & pipeline
PRECISION BIOSCIENCES INC · Data as of 2026-10-25
Upcoming catalysts
PBGENE-HBV — Full data
Late 2026
We continue our work with global investigators for next phase study design and expect to provide additional updates on the ELIMINATE-B trial progress by the end of 2026.Source filing
azercabtagene zapreleucel — Conference presentation
H2 2026
Anticipated 2026 events include presentation of preliminary Phase 1 azer-cel data in progressive multiple sclerosis in the second half of 2026 and commencement of additional exploratory studies in autoimmune diseases outside of multiple sclerosis.Source filing